LINCOLN, NE [April 14th, 2026] – Nordmark Collagenases NB Research Grade products are now available for purchase in North America directly through LICORbio. Customers in Europe, as well as LICORbio’s distribution partners, will continue to purchase these products through SERVA’s headquarters in Heidelberg, Germany.
Through the recent acquisition of SERVA Electrophoresis, LICORbio has also strengthened its connection with Nordmark Pharma GmbH, SERVA’s long-standing partner in collagenase distribution. SERVA and Nordmark have collaborated in the distribution of collagenase products for more than a decade. Effective January 1, 2026, SERVA became the global distributor of Nordmark Pharma GmbH’s research-grade collagenase portfolio.
Manufactured by Nordmark Pharma GmbH, these highly specialized enzymes are essential tools for tissue dissociation and the isolation of a wide range of cell types, supporting applications in both research and clinical development. One of the key advantages of the Nordmark portfolio is its breadth, spanning from higher side-activity blends to highly purified, low side-activity products. This range allows researchers to select the enzyme profile best suited to their application, balancing cell sensitivity and yield.
In addition, the portfolio supports workflow continuity from early research through process development. Customers can optimize their protocols using research-grade collagenases and then transition to sterile and GMP-manufactured options with equivalent enzyme choices across grades, helping to streamline tech transfer and scale-up.
“We are pleased to expand access to these high-quality enzymes for customers in the U.S.,” said Bambi Reynolds, Sr. Vice President, Commercial Strategy and Partnerships of LICORbio. “This addition to our portfolio continues our strategy of providing complete solutions that differentiate LICORbio in the marketplace and address the real challenges researchers face across their entire workflow.”
The launch also complements the recent introduction of the LICORbio Atlas™ Imager, a new platform built on fluorescent imaging technology pioneered in 2001. With expanded channel capacity, broader application support, and innovations in both 2D and 3D cell imaging, the LICORbio Atlas Imager is designed to help researchers generate deeper insights across a wide range of workflows.
Katie Schaepe
Vice President of Global Marketing
LICORbio
katie.schaepe@licorbio.com
402-467-0800